Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEDALO: daratumumab, pomalidomide and dexamethasone in del(17p) relapsed/refractory multiple myeloma
2018-002090-21Phase 2Active
- Sponsor
- Fondazione EMN Italy
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab, pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by Fondazione EMN Italy. Primary endpoint: Primary efficacy endpoint. Started Jun 2021; status: active.
02
Drugs
daratumumabpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-002090-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002090-21.